On September 3, 2026 Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, reported the appointment of Ching-Pin ("CP") Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Chang is a physician-scientist and accomplished research leader with more than two decades of experience spanning academic medicine, foundational research, and drug discovery. He joins Eikon from Bristol Myers Squibb, where he most recently served as Vice President, Head of Cardiovascular Discovery Biology and Translational Pharmacology.
"CP is an exceptional physician-scientist whose pioneering basic research in developmental genetics and cardiomyopathies while a student, post-doctoral fellow, and faculty member at Stanford University led to leadership roles in the biopharmaceutical industry, where he demonstrated an ability to translate deep insights about human disease biology into transformative therapies," said Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer of Eikon Therapeutics. "His scientific judgment, translational expertise, and experience building high-performing research organizations will be invaluable as we apply our differentiated discovery capabilities to create important new medicines."
Prior to joining Bristol Myers Squibb, Dr. Chang served as Head of Cardiovascular Research at Gilead Sciences and then as Vice President of Disease Biology at MyoKardia, where he built a disease biology program focused on understanding and targeting the genetic causes of cardiomyopathies and the characterization of mavacamten, which was later approved for the treatment of hypertrophic cardiomyopathy.
"It’s an honor to join Eikon and work alongside leaders who have helped develop some of the most important medicines of our time," said Dr. Chang. "This is an exciting moment for the company as its late-stage portfolio advances and technology and AI opens new possibilities across drug discovery and development. With its ability to generate novel biological data at exceptional scale, Eikon is well positioned to capitalize on these advances and bring breakthrough therapeutics to patients with serious illnesses."
In addition to his industry experience, Dr. Chang built an accomplished academic career centered on developmental genetics, especially as related to cardiomyopathies. He established his own laboratory at Stanford to study genetic, epigenetic, and RNA-based mechanisms underlying abnormal cardiovascular development and heart failure. He later moved his laboratory to Indiana University School of Medicine where he held the Charles Fisch Endowed Chair of Cardiology and also directed Molecular and Translational Medicine at the Krannert Institute of Cardiology.
Dr. Chang completed his medical degree at National Taiwan University before moving to the United States, where he earned his Ph.D. in cancer biology at Stanford University, focusing on molecular interactions between protooncogenes and oncogenic mechanisms. He went on to complete medical residency training at Massachusetts General Hospital, a cardiology fellowship at Stanford University, and a physician-scientist research fellowship at the Howard Hughes Medical Institute, a training arc that grounded him both in clinical practice and in fundamental research.
(Press release, Eikon Therapeutics, SEP 3, 2026, View Source [SID1234670588])